Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3488 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 18 19 20 ... 33 34 35  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Microcaps–SEVERAL: investment, 202101 seed financing round CHF5m co-led by Helvetica Capital + ZKB 2021-01-26
Cellvie–Forever Healthy: investment, 202101 seed financing round totalling $5m incl lead investor Kizoo Technology Capital 2021-01-25
Cellvie–SEVERAL: investment, 202101 seed financing round $5m led by Kizoo Technology Capital 2021-01-25
CureVac–SEVERAL: investment, 202101–202102 follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share 2021-01-25
i3 Membrane–High-Tech Gründerfonds: investment, 202101 financing round totalling 7-figure € sum inkl existing investor HTGF 2021-01-25
i3 Membrane–OTHER: investment, 202101 financing round totalling 7-figure € sum incl three private investors 2021-01-25
i3 Membrane–SEVERAL: investment, 202101 financing round 7-figure € sum from HTGF + three private investors 2021-01-25
TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund 2021-01-25
TScan Therapeutics–SEVERAL: investment, 202101 financing round Series C $100m incl new investors Black Rock + RA Capital 2021-01-25
Numares–Bruker: NMR spectroscopy, 202102– collab developm + product integration Axinon platform for metabolomics-based NMR-CDx 2021-01-21
AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones 2021-01-20
Biophytis–SEVERAL: investment, 202101– US IPO of ADSs up to $14.95m at Nasdaq 2021-01-20
Relief Therapeutics–MC Services: public relations, 202101 service existent by MC Services 2021-01-20
LignoPure–Hamburg (govt): investment, 202101 seed financing round totalling €2.2m incl investor Innovationsstarter Fonds Hamburg GmbH 2021-01-18
LignoPure–High-Tech Gründerfonds: investment, 202101 seed financing round totalling €2.2m incl investor HTGF 2021-01-18
LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG 2021-01-18
LignoPure–Tanovis: investment, 202101 seed financing round totalling €2.2m incl investor Tanovis AG 2021-01-18
IO Biotech–HBM: investment, 202101 financing round Series B totalling €127m incl new + lead investor HBM Healthcare Investments 2021-01-13
IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments 2021-01-13
Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors 2021-01-13
Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share 2021-01-12
Corat Therapeutics–Lower Saxony (govt): investment, 202101 2nd financing round incl existing investor NBank Capital 2021-01-12
Corat Therapeutics–OTHER: investment, 202101 2nd financing round incl private investors from Braunschweig 2021-01-12
Corat Therapeutics–SEVERAL: investment, 202101 2nd financing round from NBank Capital + private investors 2021-01-12
Delfi Diagnostics–Allianz: investment, 202101 financing round Series A totalling $100m incl existing + co-investor AV8 Ventures 2021-01-12
Delfi Diagnostics–SEVERAL: investment, 202101 financing round Series A $100m led by OrbiMed 2021-01-12
ZytoVision–ArchiMed: investment, 202101 acquisition of majority in Zytomed Systems + ZytoVision + 42 Life Sciences by MED II Fund new holding ZytoMax 2021-01-12
Addex–SEVERAL: investment, 202101 capital increase global offering $11.5m with 6.9m new shares (thereof 6.75m in form of ADSs 2021-01-11
Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based 2021-01-11
Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI 2021-01-11
Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED 2021-01-11
Labforward–2mag: investment, 202101 financing round Series B totalling >€5m incl new + co-investor 2mag 2021-01-11
Labforward–Peppermint: investment, 202101 financing round Series B totalling >€5m incl existing + co-investor Peppermint VenturePartners 2021-01-11
Labforward–SEVERAL: investment, 202101 financing round Series B >€5m led by Tecan + incl 2mag + Peppermint VenturePartners 2021-01-11
Labforward–Tecan: investment, 202101 financing round Series B totalling >€5m incl €4m from new + lead investor Tecan resulting in 10% stake 2021-01-11
Novartis–BeiGene: tisleizumab, 202101–202309 license $650m upfront + royalties + milestones developm + commercialisation in US et la TERMINATED 9/23 2021-01-11
Valo Health–Canada (govt): investment, 202101 financing round Series B totalling $190m incl lead investor PSP Investments 2021-01-11
Valo Health–HBM: investment, 202101 financing round Series B totalling $190m incl new + co-investor HBM Healthcare Investments 2021-01-11
Valo Health–SEVERAL: investment, 202101 financing round Series B $190m led by PSP Investments 2021-01-11
Biogen–Cevec: cell line technology, 202101– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies 2021-01-08
AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck 2021-01-07
Bayer–Turbine: AI-based drug discovery, <=202101 collaboration 2021-01-07
BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund 2021-01-07
BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital 2021-01-07
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al 2021-01-07
Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies 2021-01-07
Scorpion Therapeutics–SEVERAL: investment, 202101 financing round Series B $162m led by Boxer Capital + EcoR1 Capital + Omega Funds + Vida Ventures 2021-01-07
Sterna Biologicals–SEVERAL: investment, 202101 financing round Series A 2nd closing €10m bringing total Series A to €22m 2021-01-07
Turbine–Atlantic Labs: investment, 202101 financing round pre-Series A totalling €5.7m incl existing + co-investor Atlantic Labs 2021-01-07
Turbine–o2h: investment, 202101 financing round pre-Series A totalling €5.7m incl existing + co-investor o2h Ventures 2021-01-07
Turbine–SEVERAL: investment, 202101 financing round pre-Series A €5.7m led by Accel 2021-01-07
Adeptrix–Bruker: investment, 202101 financing round Series A incl new + minority investor Bruker Corp 2021-01-06
Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp 2021-01-06
Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 2021-01-06
Novasep–Sartorius: investment, 202101– acquisition €na of Novasep’s chromatography process equipment division by Sartorius ANNOUNCED 2021-01-06
Senti Biosciences–Bayer: investment, 202101 financing round Series B totalling $105m incl new + lead investor Leaps by Bayer 2021-01-06
Senti Biosciences–SEVERAL: investment, 202101 financing round Series B $105m led by Leaps by Bayer 2021-01-06
Terns Pharmaceuticals–Samsara Capital: investment, 202101 financing round Series C totalling $87m incl co-investor Samsara Capital 2021-01-05
Terns Pharmaceuticals–SEVERAL: investment, 202101 financing round Series C $87m led by Deerfield Management 2021-01-05
Arvelle Therapeutics–Angelini: investment, 202101– acquisition merger up to $960m in cash with $610m after approval of cenobamate + $350m milestones 2021-01-04
Somatex Medical Technologies–Hologic: investment, 202101 acquisition $64m of Somatex by Hologic 2021-01-04
Aerium Therapeutics–Omega Funds: investment, 2021 seed investment + incubation of Aerium by Omega Funds 2021-01-01
BigOmics–SEVERAL: investment, 2021 seed financing round $430k from TiVentures + ADM Partners 2021-01-01
Biosun Biochemicals–BRAIN Biotech: investment, 202101 acquisition 100% €na by BRAIN AG 2021-01-01
Complement Therapeutics–BioGeneration Ventures: investment, 2021 initial funding of spin-out from Univ of Manchester from BGV 2021-01-01
Cutanos–Max Planck: topical drug delivery technology, 202101– license excl to LC-TDS technology from Max Planck Innovation 2021-01-01
Dualyx–High-Tech Gründerfonds: investment, 2021c seed financing round totalling €7m incl investor HTGF 2021-01-01
Dualyx–SEVERAL: investment, 2021c seed financing round €7m from V-Bio Ventures + BGV + PMV + VIB + HTGF + GFF 2021-01-01
Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use 2021-01-01
Smartbax–Boehringer: investment, 2021 pre-seed financing €700k from BIVF 2021-01-01
Cajal Neuroscience–Evotec: investment, 202012 existent Evotec owns 1.82% of voting rights 2020-12-31
Dark Blue Therapeutics–Evotec: investment, 202012 existent Evotec owns 18.67% of voting rights 2020-12-31
Mission BioCapital–Evotec: investment, 202012 existent Evotec owns 7.22% of voting rights of Mission BioCapital V LP 2020-12-31
NephThera–Evotec: investment, 202012 existent Evotec owns 50.00% of voting rights 2020-12-31
SomaLogic–Novartis: investment, 202012 financing round Series A 2nd closing totalling addit $81m incl Novartis 2020-12-22
SomaLogic–SEVERAL: investment, 202012 financing round Series A 2nd closing additional $81m bringing total Series A to $204m or $214m 2020-12-22
Evotec–Alloy Therapeutics: transgenic mouse technolgy, 202012– supply access to ATX-Gx platform to expand Evotec antibody discovery platform 2020-12-21
Peptilogics–Angermayer Group: investment, 202012 financing round Series B totalling $35.4m incl new + lead investor Presight Capital 2020-12-21
Peptilogics–SEVERAL: investment, 202012 financing round Series B $35.4m led by Presight Capital 2020-12-21
V7–Miele: investment, 202012 seed financing round totalling $3m incl co-investor Miele Venture 2020-12-18
V7–SEVERAL: investment, 202012 seed financing round $3m led by Amadeus Capital Partners 2020-12-18
Cadent Therapeutics–Novartis: investment, 202012– acquisition $210m upfront + $560m milestones ANNOUNCED 2020-12-17
ECBF–SEVERAL: investment, 202012–202202 raising of additional €125m + final closing of fund at €300m 2020-12-16
Exo Therapeutics–Novartis: investment, 202012 financing round Series A totalling $25m incl investor Novartis Venture Fund 2020-12-16
Exo Therapeutics–SEVERAL: investment, 202012 financing round Series A $25m incl Newpath Partners + NVF + CRV + 6 Dimensions Capital 2020-12-16
Neuron23–SEVERAL: investment, 202012 financing round Series B $80m led by new investor Redmile Group 2020-12-16
ECBF–Neste: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Neste 2020-12-15
ECBF–Nestlé: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Nestlé 2020-12-15
ECBF–North Rhine-Westphalia (govt): investment, 202012 2nd closing with additional sum totalling €93m incl new investor NRW.Bank 2020-12-15
ECBF–OTHER: investment, 202012 2nd closing with additional sum totalling €93m incl undisclosed family office as new investor 2020-12-15
ECBF–SEVERAL: investment, 202012 2nd closing with additional €93m from new investors bringing total to €175m 2020-12-15
ECBF–Volkswohl Bund: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Volkswohl Bund Versicherungen 2020-12-15
MYR GmbH–Gilead: investment, 202012 acquisition €1.15b in cash + €300m milestones of MYR GmbH by Gilead Sciences Inc 2020-12-10
NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer 2020-12-10
Resolve Biosciences–Alafi Capital: investment, 202012 financing round Series A totalling $24m incl co-investor Alafi Capital 2020-12-10
Resolve Biosciences–Bioscribe: public relations, 202012 service existent by Bioscribe 2020-12-10
Resolve Biosciences–High-Tech Gründerfonds: investment, 202012 financing round Series A totalling $24m incl co-investor HTGF 2020-12-10
Resolve Biosciences–MasterMind Advisory Services: investment, 202012 financing round Series A totalling $24m incl co-lead investor MasterMind 2020-12-10
Resolve Biosciences–PERSON: investment, 202012 financing round Series A totalling $24m incl co-investor John Shoffner 2020-12-10
Resolve Biosciences–PS Capital Management: investment, 202012 financing round Series A totalling $24m incl co-lead investor PS Capital 2020-12-10
next pagenext page 1 2 3 ... 18 19 20 ... 33 34 35  next pagenext page



Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top